Transformative develops patented software that predicts sudden cardiac arrest by analyzing data from patient monitoring devices commonly used in hospitals. The company’s core product is designed to enable preventive care by identifying patients at risk of sudden cardiac arrest. Transformative plans to use new funding to obtain FDA clearance for its first product and to begin developing technologies to predict other life‑threatening conditions. The company was co‑founded by CEO Josh Oppenheimer, MD, MBA, Marek Sirendi, PhD, and Marek Rei, PhD. Transformative operates in the US, the UK and Estonia and was formed in 2016 through Entrepreneur First’s startup program. It also participated in the Philips HealthWorks program.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2020